서철원 교수
#림프종#다발골수종#만성림프구백혈병#헬스조선명의
|
학력
1989 .03 ~ 1994 .02 서울대학교 의학 박사
1985 .03 ~ 1987 .02 서울대학교 의학 석사
1977 .03 ~ 1983 .02 서울대학교 의학 학사
1985 .03 ~ 1987 .02 서울대학교 의학 석사
1977 .03 ~ 1983 .02 서울대학교 의학 학사
경력
2008 .03 ~ 2012 .02 서울아산병원 종양내과 과장
2002 .10 ~ 현재 울산의대 서울아산병원 종양내과 교수
1997 .10 ~ 2002 .09 울산의대 서울아산병원 종양내과 부교수
1993 .04 ~ 1997 .09울산의대 서울아산병원 종양내과 조교수
1991 .03 ~ 1993 .03 서울아산병원 종양내과 전임강사
1990 .03 ~ 1991 .02 서울아산병원 종양내과 전임의
1989 .03 ~ 1990 .02 인천중앙길병원 과장
1987 .03 ~ 1989 .02 서울대병원 혈액종양내과 전임의
1984 .03 ~ 1987 .02 서울대병원 내과 전공의
2002 .10 ~ 현재 울산의대 서울아산병원 종양내과 교수
1997 .10 ~ 2002 .09 울산의대 서울아산병원 종양내과 부교수
1993 .04 ~ 1997 .09울산의대 서울아산병원 종양내과 조교수
1991 .03 ~ 1993 .03 서울아산병원 종양내과 전임강사
1990 .03 ~ 1991 .02 서울아산병원 종양내과 전임의
1989 .03 ~ 1990 .02 인천중앙길병원 과장
1987 .03 ~ 1989 .02 서울대병원 혈액종양내과 전임의
1984 .03 ~ 1987 .02 서울대병원 내과 전공의
논문
Complete metabolic response (CMR) in positron emission tomography-computed tomography (PET-CT) scans may have prognostic significance in patients with marginal zone lymphomas (MZL).
Lymphoma epidemiology in Korea and the real clinical field including the Consortium for Improving Survival of Lymphoma (CISL) trial.
Phase I study of CKD-581, a pan-histone deacetylase inhibitor, in patients with lymphoma or multiple myeloma refractory to standard therapy.
Sequential chemotherapy/radiotherapy was comparable with concurrent chemoradiotherapy for stage I/II NK/T-cell lymphoma.
Beyond first-line non-anthracycline-based chemotherapy for extranodal NK/T-cell lymphoma: clinical outcome and current perspectives on salvage therapy for patients after first relapse and progression of disease.
Clinical characteristics, treatment, and outcome of primary rectal lymphoma: a single center experience of 16 patients.
Comprehensive evaluation of the revised international staging system in multiple myeloma patients treated with novel agents as a primary therapy.
Electrophysiological features of POEMS syndrome compared to MGUS-related neuropathy.
GLUT1 as a Prognostic Factor for Classical Hodgkin's Lymphoma: Correlation with PD-L1 and PD-L2 Expression.
Increased circulating plasma cells detected by flow cytometry predicts poor prognosis in patients with plasma cell myeloma.
Interim (18)F-FGD PET/CT may not predict the outcome in primary central nervous system lymphoma patients treated with sequential treatment with methotrexate and cytarabine.
PD-L1 expression correlates with VEGF and microvessel density in patients with uniformly treated classical Hodgkin lymphoma.
Primary central nervous system lymphoma: a new prognostic model for patients with diffuse large B-cell histology.
Relevance of prognostic index with β2-microglobulin for patients with diffuse large B-cell lymphoma in the rituximab era.
Sequential heart and autologous stem cell transplantation for light-chain cardiac amyloidosis.
The Consortium for Improving Survival of Lymphoma (CISL): recent achievements and future perspective.
The immune checkpoint molecule V-set Ig domain-containing 4 is an independent prognostic factor for multiple myeloma.
The role of frontline autologous stem cell transplantation for primary plasma cell leukemia: a retrospective multicenter study (KMM160).
Treatment outcomes of dose-attenuated CHOP chemotherapy in elderly patients with peripheral T cell lymphoma.
A new extranodal scoring system based on the prognostically relevant extranodal sites in diffuse large B-cell lymphoma, not otherwise specified treated with chemoimmunotherapy.
Assessment of bone marrow involvement in patients with lymphoma: report on a consensus meeting of the Korean Society of Hematology Lymphoma Working Party.
Bendamustine in heavily pre-treated multiple myeloma patients: Results of a retrospective analysis from the Korean Multiple Myeloma Working Party.
Cauda equina lymphoma mimicking non-neoplastic hypertrophic neuropathy of the cauda equina: A case report.
Clinical Features and Survival of Patients With Follicular Lymphoma in Korea.
Evolution of frontline treatment of diffuse large B-cell lymphoma: a brief review and recent update.
Methotrexate elimination and toxicity: MTHFR 677C>T polymorphism in patients with primary CNS lymphoma treated with high-dose methotrexate.
Occurrence of sarcoidosis after chemotherapy for non-Hodgkin lymphoma.
Phase II trial of concurrent chemoradiotherapy with L-asparaginase and MIDLE chemotherapy for newly diagnosed stage I/II extranodal NK/T-cell lymphoma, nasal type (CISL-1008).
Pneumocystis pneumonia versus rituximab-induced interstitial lung disease in lymphoma patients receiving rituximab-containing chemotherapy.
Pretreatment whole blood Epstein-Barr virus-DNA is a significant prognostic marker in patients with Hodgkin lymphoma.
Lymphoma epidemiology in Korea and the real clinical field including the Consortium for Improving Survival of Lymphoma (CISL) trial.
Phase I study of CKD-581, a pan-histone deacetylase inhibitor, in patients with lymphoma or multiple myeloma refractory to standard therapy.
Sequential chemotherapy/radiotherapy was comparable with concurrent chemoradiotherapy for stage I/II NK/T-cell lymphoma.
Beyond first-line non-anthracycline-based chemotherapy for extranodal NK/T-cell lymphoma: clinical outcome and current perspectives on salvage therapy for patients after first relapse and progression of disease.
Clinical characteristics, treatment, and outcome of primary rectal lymphoma: a single center experience of 16 patients.
Comprehensive evaluation of the revised international staging system in multiple myeloma patients treated with novel agents as a primary therapy.
Electrophysiological features of POEMS syndrome compared to MGUS-related neuropathy.
GLUT1 as a Prognostic Factor for Classical Hodgkin's Lymphoma: Correlation with PD-L1 and PD-L2 Expression.
Increased circulating plasma cells detected by flow cytometry predicts poor prognosis in patients with plasma cell myeloma.
Interim (18)F-FGD PET/CT may not predict the outcome in primary central nervous system lymphoma patients treated with sequential treatment with methotrexate and cytarabine.
PD-L1 expression correlates with VEGF and microvessel density in patients with uniformly treated classical Hodgkin lymphoma.
Primary central nervous system lymphoma: a new prognostic model for patients with diffuse large B-cell histology.
Relevance of prognostic index with β2-microglobulin for patients with diffuse large B-cell lymphoma in the rituximab era.
Sequential heart and autologous stem cell transplantation for light-chain cardiac amyloidosis.
The Consortium for Improving Survival of Lymphoma (CISL): recent achievements and future perspective.
The immune checkpoint molecule V-set Ig domain-containing 4 is an independent prognostic factor for multiple myeloma.
The role of frontline autologous stem cell transplantation for primary plasma cell leukemia: a retrospective multicenter study (KMM160).
Treatment outcomes of dose-attenuated CHOP chemotherapy in elderly patients with peripheral T cell lymphoma.
A new extranodal scoring system based on the prognostically relevant extranodal sites in diffuse large B-cell lymphoma, not otherwise specified treated with chemoimmunotherapy.
Assessment of bone marrow involvement in patients with lymphoma: report on a consensus meeting of the Korean Society of Hematology Lymphoma Working Party.
Bendamustine in heavily pre-treated multiple myeloma patients: Results of a retrospective analysis from the Korean Multiple Myeloma Working Party.
Cauda equina lymphoma mimicking non-neoplastic hypertrophic neuropathy of the cauda equina: A case report.
Clinical Features and Survival of Patients With Follicular Lymphoma in Korea.
Evolution of frontline treatment of diffuse large B-cell lymphoma: a brief review and recent update.
Methotrexate elimination and toxicity: MTHFR 677C>T polymorphism in patients with primary CNS lymphoma treated with high-dose methotrexate.
Occurrence of sarcoidosis after chemotherapy for non-Hodgkin lymphoma.
Phase II trial of concurrent chemoradiotherapy with L-asparaginase and MIDLE chemotherapy for newly diagnosed stage I/II extranodal NK/T-cell lymphoma, nasal type (CISL-1008).
Pneumocystis pneumonia versus rituximab-induced interstitial lung disease in lymphoma patients receiving rituximab-containing chemotherapy.
Pretreatment whole blood Epstein-Barr virus-DNA is a significant prognostic marker in patients with Hodgkin lymphoma.
저서
저서 내용이 없습니다.
보도자료
전문의들 100문 100답 ‘림프종 바로알기’ 출간
http://news.khan.co.kr/kh_news/khan_art_view.html?artid=201706132107025&code=900303
"1~2년 더 살릴 수 있는 약, 쓰고 싶다"
http://www.dailypharm.com/News/213597
"생존율 높아진 다발골수종, 신약 접근성이 관건"
http://medipana.com/news/news_viewer.asp?NewsNum=183954&MainKind=A&NewsKind=5&vCount=12&vKind=1
http://news.khan.co.kr/kh_news/khan_art_view.html?artid=201706132107025&code=900303
"1~2년 더 살릴 수 있는 약, 쓰고 싶다"
http://www.dailypharm.com/News/213597
"생존율 높아진 다발골수종, 신약 접근성이 관건"
http://medipana.com/news/news_viewer.asp?NewsNum=183954&MainKind=A&NewsKind=5&vCount=12&vKind=1
포스팅
Characteristics of MYC Gene Aberrations in Multiple Myeloma
A Case of Bone Marrow Involvement of Large B-Cell Lymphoma in Angioimmunoblastic T-Cell Lymphoma
Multiple mononeuropathy in a patient with extranodal NK/T cell lymphoma
The efficacy of systemic high dose methotrexate as central nervous system prophylaxis in patients with high risk diffuse large B-cell lymphoma: A propensity score-matched analysis
Final Report on Phase II Trial of L-AsparaginasePlus Concurrent ChemoradiotherapyFollowed By Midle(Methotrexate, Ifosfamide, Etoposide, Dexamethasone, and L-asparaginase)
Chemotherapy for Patients with Newly Diagnosed Stage I/II ExtranodalNK/T-Cell L
Clinical outcomes after autologous stem cell transplantation in young multiple myeloma patients with renal impairment
Thiotepa Containing Regimen as Conditioning Chemotherapy for Lymphoma Involving Central Nervous System Compared With BuCyE (Busulfan, Cyclophosphamide and Etoposide)
A New Prognostic Index for Multiple Myeloma Patients in the Era of Novel Agents.
Treatment of primary testicular diffuse large B cell lymphoma without prophylactic intrathecal chemotherapy: a single center experience
Interim PET-CT as a prognostic tool for predicting clinical outcomes in nodal type T-cell non-Hodgkin lymphoma
Peripheral Blood Hematopoietic Progenitor Cell (HPC) Counts at Autologous Stem Cell Collection (ASCC) are Associated with Prognosis in Multiple Myeloma
Intravascular large B-cell lymphoma in Korea: Clinical and pathological findings
Multiple Myeloma Screening Panel for Detection of Monoclonal Protein in Korean Patients
Simplified Immunophenotyping Panel for Multiple Myeloma to differentiate neoplastic myeloma cells from reactive plasma cells
High-dose chemotherapy and autologous stem-cell transplantation for Korean patients with relapsed or refractory Hodgkin lymphoma
The role of high dose chemotherapy and autologous stem cell transplantation for relapsed T-cell lymphoma
A Case of Bone Marrow Involvement of Large B-Cell Lymphoma in Angioimmunoblastic T-Cell Lymphoma
Multiple mononeuropathy in a patient with extranodal NK/T cell lymphoma
The efficacy of systemic high dose methotrexate as central nervous system prophylaxis in patients with high risk diffuse large B-cell lymphoma: A propensity score-matched analysis
Final Report on Phase II Trial of L-AsparaginasePlus Concurrent ChemoradiotherapyFollowed By Midle(Methotrexate, Ifosfamide, Etoposide, Dexamethasone, and L-asparaginase)
Chemotherapy for Patients with Newly Diagnosed Stage I/II ExtranodalNK/T-Cell L
Clinical outcomes after autologous stem cell transplantation in young multiple myeloma patients with renal impairment
Thiotepa Containing Regimen as Conditioning Chemotherapy for Lymphoma Involving Central Nervous System Compared With BuCyE (Busulfan, Cyclophosphamide and Etoposide)
A New Prognostic Index for Multiple Myeloma Patients in the Era of Novel Agents.
Treatment of primary testicular diffuse large B cell lymphoma without prophylactic intrathecal chemotherapy: a single center experience
Interim PET-CT as a prognostic tool for predicting clinical outcomes in nodal type T-cell non-Hodgkin lymphoma
Peripheral Blood Hematopoietic Progenitor Cell (HPC) Counts at Autologous Stem Cell Collection (ASCC) are Associated with Prognosis in Multiple Myeloma
Intravascular large B-cell lymphoma in Korea: Clinical and pathological findings
Multiple Myeloma Screening Panel for Detection of Monoclonal Protein in Korean Patients
Simplified Immunophenotyping Panel for Multiple Myeloma to differentiate neoplastic myeloma cells from reactive plasma cells
High-dose chemotherapy and autologous stem-cell transplantation for Korean patients with relapsed or refractory Hodgkin lymphoma
The role of high dose chemotherapy and autologous stem cell transplantation for relapsed T-cell lymphoma
영상자료
영상자료 내용이 없습니다.
발표자료
Epidermal growth factor receptor tyrosine kinase inhibitors as a first-line therapy for never smokers with adenocarcinoma of the lung and asymptomatic synchronous brain metastasis.
A phase I and pharmacologic study of Belotecan in combination with Cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer
Induction chemotherapy followed by concurrent chemoradiotherapy (CCRT) versus CCRT alone for unresectable stage III non-small cell lung cancer (NSCLC): randomized phase III trial.
Assessments of the epidermal growth factor receptor mutations and amplification and their clinical implication in patients with lung adeno-carcinoma
Neoadjuvant weekly paclitaxel/cisplatin chemotherapy (WPC) with concurrent thoracic radiation (TR) followed by surgical resection (S) for pathologically proven N2 (pN2) stage IIIA non-small cell lung
Epidermal growth factor receptor (EGFR) and KRAS mutations in non-small cell lung cancer (nsclc) patients treated with gefitinib
Bortezomib, Doxorubicin and Dexamethasone (PAD) Combination Therapy Followed by Thalidomide and Dexamethasone (TD) as a Salvage Treatment for Relapsed Multiple Myeloma (MM)
Sequential VAD (Vincristine, Adriamycin, Dexamethasone) and VTD (VELCADE, Thalidomide, Dexamethasone) Induction Followed by High-Dose Therapy
The Clinical Outcomes of Autologous Stem Cell Transplantation in Peripheral T Cell Lymphoma: from Retrospective Multicenter Study in Korea.
A Multicenter Phase II Trial of Etoposide, Methylprednisolone, High-Dose Cytarabine, and Oxaliplatin (ESHAOx) for Patients with Refractory/Relapsed Aggressive Non-Hodgkins Lymphoma.
Multicenter Phase II Trial of 90Y-Ibritumomab Tiuxetan with High-Dose Chemotherapy (Busulfan/Cyclophosphamide/Etoposide) Followed by Autologous Stem Cell Transplantation in Relapsed
Prospective Randomized Phase Ⅲ Trial of KROG 03-02 on the Induction Chemotherapy in the Concurrent Chemoradiotherapy for the Locally Advanced Non-Small Cell Lung Cancer
Neoadjuvant weekly paclitaxel/cisplatin chemotherapy (WPC) with concurrent thoracic radiation (TR) followed by surgical resection (S) for pathologically proven N2 (pN2) stage IIIA non-small cell lung
A phase I and pharmacologic study of Belotecan in combination with Cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer
Induction chemotherapy followed by concurrent chemoradiotherapy (CCRT) versus CCRT alone for unresectable stage III non-small cell lung cancer (NSCLC): randomized phase III trial.
Assessments of the epidermal growth factor receptor mutations and amplification and their clinical implication in patients with lung adeno-carcinoma
Neoadjuvant weekly paclitaxel/cisplatin chemotherapy (WPC) with concurrent thoracic radiation (TR) followed by surgical resection (S) for pathologically proven N2 (pN2) stage IIIA non-small cell lung
Epidermal growth factor receptor (EGFR) and KRAS mutations in non-small cell lung cancer (nsclc) patients treated with gefitinib
Bortezomib, Doxorubicin and Dexamethasone (PAD) Combination Therapy Followed by Thalidomide and Dexamethasone (TD) as a Salvage Treatment for Relapsed Multiple Myeloma (MM)
Sequential VAD (Vincristine, Adriamycin, Dexamethasone) and VTD (VELCADE, Thalidomide, Dexamethasone) Induction Followed by High-Dose Therapy
The Clinical Outcomes of Autologous Stem Cell Transplantation in Peripheral T Cell Lymphoma: from Retrospective Multicenter Study in Korea.
A Multicenter Phase II Trial of Etoposide, Methylprednisolone, High-Dose Cytarabine, and Oxaliplatin (ESHAOx) for Patients with Refractory/Relapsed Aggressive Non-Hodgkins Lymphoma.
Multicenter Phase II Trial of 90Y-Ibritumomab Tiuxetan with High-Dose Chemotherapy (Busulfan/Cyclophosphamide/Etoposide) Followed by Autologous Stem Cell Transplantation in Relapsed
Prospective Randomized Phase Ⅲ Trial of KROG 03-02 on the Induction Chemotherapy in the Concurrent Chemoradiotherapy for the Locally Advanced Non-Small Cell Lung Cancer
Neoadjuvant weekly paclitaxel/cisplatin chemotherapy (WPC) with concurrent thoracic radiation (TR) followed by surgical resection (S) for pathologically proven N2 (pN2) stage IIIA non-small cell lung